A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

Project: Other project

StatusActive
Effective start/end date6/6/186/5/23

Funding

  • Mitsubishi Tanabe Pharma: $213,384.00